雄激素剥夺疗法
内科学
肿瘤科
泌尿科
前列腺
雄激素
睾丸切除术
癌症
作者
Mark C. Markowski,Pedro Isaacsson Velho,Mario A. Eisenberger,Martin G. Pomper,Kenneth J. Pienta,Michael A. Gorin,Emmanuel S. Antonarakis,Samuel R. Denmeade,Steven P. Rowe
标识
DOI:10.2967/jnumed.120.259226
摘要
Rationale: Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule positron emission tomography (PET) radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT.
Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 months of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion.
Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All three had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT and/or bone scan was observed within 3 months of progression on 18F-DCFPyL PET/CT. For the 3 patients that did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for > 6 months.
Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI